Prevalence and Impact of Steatotic Liver Disease in Autoimmune Liver Diseases: A Systematic Review and Meta‐Analysis
Liver International · 2026-06 · 46 (6)
DOI: 10.1111/liv.70694 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Liver International, online erschienen am 19.05.2026. Verfasst von Ivanna Diaz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, SUNY Downstate Health Sciences University, Brooklyn, New York, USA. Hauptthemen laut MEDLINE: Fatty Liver, Hepatitis, Autoimmune, Cholangitis, Sclerosing, Liver Cirrhosis, Biliary. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben.
Abstract (Originalsprache)
Autoimmune liver diseases (AILDs), including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), can coexist with steatotic liver disease (SLD); however, this overlap has not been systematically assessed. We aimed to determine the prevalence, clinical characteristics and outcomes of SLD in patients with AILDs. In this systematic review and meta‐analysis, we searched PubMed and Embase from inception to May 20, 2025 for observational studies reporting on hepatic steatosis in AILDs. Proportions were pooled using a generalized linear mixed model and pairwise meta‐analyses used random‐effects models to obtain pooled odds ratios (ORs) or standardized mean differences. PROSPERO ID: CRD420251057378. Forty‐seven studies ( N = 10 734) were included. SLD prevalence was 29.7% (95% confidence interval [CI] 21.9–39.0, τ 2 = 0.923, I 2 = 94.2%) in AIH, 25.0% (95% CI 16.1–36.6, τ 2 = 1.418, I 2 = 94.7%) in PBC, and 17.1% (95% CI 10.8–26.0, τ 2 = 0.500, I 2 = 90.8%) in PSC. Patients with AILDs and SLD had a higher body mass index and a greater burden of metabolic comorbidities. In AIH, SLD was associated with lower liver enzymes, but increased odds of significant (OR 1.37, 95% CI 1.02–1.84, τ 2 = 0, I 2 = 0%) and advanced fibrosis (OR 1.84, 95% CI 1.37–2.47, τ 2 = 0.024, I 2 = 17.4%). Evidence on the prognostic impact of SLD in AILDs was limited and inconsistent, with no studies reporting on PSC. SLD is common across AILDs and may modify their clinical and prognostic profiles, especially in AIH. These data support potential systematic metabolic screening and multidisciplinary care in this population. Further research is needed to clarify the prognostic significance of SLD and inform risk stratification and management in AILDs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, SUNY Downstate Health Sciences University, Brooklyn, New York, USA.
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
- Department of Internal Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
ORCID-Profile: Ivanna Diaz, Saeed Ahmad, Pojsakorn Danpanichkul, Matheus Souza
Zitieren
APA
Diaz, I., Ahmad, S., Danpanichkul, P., & Souza, M. (2026). Prevalence and Impact of Steatotic Liver Disease in Autoimmune Liver Diseases: A Systematic Review and Meta‐Analysis. Liver International, 46(6). https://doi.org/10.1111/liv.70694
Vancouver
Diaz I, Ahmad S, Danpanichkul P, Souza M. Prevalence and Impact of Steatotic Liver Disease in Autoimmune Liver Diseases: A Systematic Review and Meta‐Analysis. Liver International. 2026;46(6). doi:10.1111/liv.70694
BibTeX
@article{Diaz2026,
author = {Diaz, Ivanna and Ahmad, Saeed and Danpanichkul, Pojsakorn and Souza, Matheus},
title = {Prevalence and Impact of Steatotic Liver Disease in Autoimmune Liver Diseases: A Systematic Review and Meta‐Analysis},
journal = {Liver International},
year = {2026},
volume = {46},
number = {6},
doi = {10.1111/liv.70694}
}
EUVIMED